Matches in Wikidata for { <http://www.wikidata.org/entity/Q94409621> ?p ?o ?g. }
Showing items 1 to 63 of
63
with 100 items per page.
- Q94409621 description "article scientifique publié en 2017" @default.
- Q94409621 description "wetenschappelijk artikel" @default.
- Q94409621 description "наукова стаття" @default.
- Q94409621 name "STEM-32. PRE-CLINICAL SAFETY AND EFFICACY STUDIES OF NEURAL STEM CELL MEDIATED CARBOXYLESTERASE/IRINOTECAN ENZYME/PRODRUG GENE THERAPY FOR RECURRENT GLIOMA LEADING TO FIRST-IN-HUMAN PHASE I CLINICAL TRIAL" @default.
- Q94409621 name "STEM-32. PRE-CLINICAL SAFETY AND EFFICACY STUDIES OF NEURAL STEM CELL MEDIATED CARBOXYLESTERASE/IRINOTECAN ENZYME/PRODRUG GENE THERAPY FOR RECURRENT GLIOMA LEADING TO FIRST-IN-HUMAN PHASE I CLINICAL TRIAL" @default.
- Q94409621 type Item @default.
- Q94409621 label "STEM-32. PRE-CLINICAL SAFETY AND EFFICACY STUDIES OF NEURAL STEM CELL MEDIATED CARBOXYLESTERASE/IRINOTECAN ENZYME/PRODRUG GENE THERAPY FOR RECURRENT GLIOMA LEADING TO FIRST-IN-HUMAN PHASE I CLINICAL TRIAL" @default.
- Q94409621 label "STEM-32. PRE-CLINICAL SAFETY AND EFFICACY STUDIES OF NEURAL STEM CELL MEDIATED CARBOXYLESTERASE/IRINOTECAN ENZYME/PRODRUG GENE THERAPY FOR RECURRENT GLIOMA LEADING TO FIRST-IN-HUMAN PHASE I CLINICAL TRIAL" @default.
- Q94409621 prefLabel "STEM-32. PRE-CLINICAL SAFETY AND EFFICACY STUDIES OF NEURAL STEM CELL MEDIATED CARBOXYLESTERASE/IRINOTECAN ENZYME/PRODRUG GENE THERAPY FOR RECURRENT GLIOMA LEADING TO FIRST-IN-HUMAN PHASE I CLINICAL TRIAL" @default.
- Q94409621 prefLabel "STEM-32. PRE-CLINICAL SAFETY AND EFFICACY STUDIES OF NEURAL STEM CELL MEDIATED CARBOXYLESTERASE/IRINOTECAN ENZYME/PRODRUG GENE THERAPY FOR RECURRENT GLIOMA LEADING TO FIRST-IN-HUMAN PHASE I CLINICAL TRIAL" @default.
- Q94409621 P1433 Q94409621-46F53279-D8C5-43C4-8AFC-DD79482640CB @default.
- Q94409621 P1476 Q94409621-085B499D-E42A-4E07-A526-86A920445BF4 @default.
- Q94409621 P2093 Q94409621-0F8CD660-0B63-49E5-A9F1-BE4CC37DF437 @default.
- Q94409621 P2093 Q94409621-121AF50A-58D9-45C1-9AA0-B39ED8AAD626 @default.
- Q94409621 P2093 Q94409621-1F63EA47-CF91-4D44-BC62-15BDE336BD77 @default.
- Q94409621 P2093 Q94409621-358A6FB8-D60C-47E5-B832-674CDFA0109C @default.
- Q94409621 P2093 Q94409621-5549F8F9-267D-4573-8968-C247F37B502E @default.
- Q94409621 P2093 Q94409621-59DD72E3-A292-4E64-BAD5-88851A7F389F @default.
- Q94409621 P2093 Q94409621-5A577CC4-EFFD-4047-BE02-DF6BCE2B00E7 @default.
- Q94409621 P2093 Q94409621-8ABEC9D1-ABB1-493C-A2BA-0DA4BA18DBAF @default.
- Q94409621 P2093 Q94409621-8BE52512-A328-4B58-A0A5-C8F503C33DD2 @default.
- Q94409621 P2093 Q94409621-8FB43794-5D82-47DB-8E2E-E2095ACE46D0 @default.
- Q94409621 P2093 Q94409621-C4CF69EA-4959-42CE-8171-A20D94805D4D @default.
- Q94409621 P2093 Q94409621-CCD7C1B1-2936-4ADC-A07F-BBC858B12A2F @default.
- Q94409621 P2093 Q94409621-D6B6B260-B3A8-4BCD-ABCB-B167C0E1999B @default.
- Q94409621 P2093 Q94409621-F8B2558C-B6C6-4AF3-BDB4-9F20FE7A8357 @default.
- Q94409621 P304 Q94409621-AEDD9093-A89B-4DC5-BB48-164BADD23271 @default.
- Q94409621 P31 Q94409621-402137BA-CE90-4CAD-AEEC-742AF5CD8CAA @default.
- Q94409621 P356 Q94409621-7173A397-0668-4C69-9378-48D548905E8C @default.
- Q94409621 P433 Q94409621-C6AF4295-FC11-4878-858C-9870A7ABC09C @default.
- Q94409621 P478 Q94409621-24BF4EEC-E081-4D1E-B3CE-7B43D06CDBEF @default.
- Q94409621 P50 Q94409621-E26DD21E-C5C3-4C52-B5ED-AAFAA0BDC38E @default.
- Q94409621 P577 Q94409621-F0E24077-EAF1-4D2F-B4D4-FAAA9F779221 @default.
- Q94409621 P921 Q94409621-63074865-011E-4909-B085-C310F455CEE0 @default.
- Q94409621 P921 Q94409621-8A92AA59-D09E-48AC-AAB8-2059FF47C3BB @default.
- Q94409621 P932 Q94409621-6DE3E68D-FCD8-425B-B25B-604A23AB7149 @default.
- Q94409621 P356 NOX168.947 @default.
- Q94409621 P1433 Q15724471 @default.
- Q94409621 P1476 "STEM-32. PRE-CLINICAL SAFETY AND EFFICACY STUDIES OF NEURAL STEM CELL MEDIATED CARBOXYLESTERASE/IRINOTECAN ENZYME/PRODRUG GENE THERAPY FOR RECURRENT GLIOMA LEADING TO FIRST-IN-HUMAN PHASE I CLINICAL TRIAL" @default.
- Q94409621 P2093 "Christine Brown" @default.
- Q94409621 P2093 "Jana Portnow" @default.
- Q94409621 P2093 "Lucy Ghoda" @default.
- Q94409621 P2093 "Margarita Gutova" @default.
- Q94409621 P2093 "Marianne Metz" @default.
- Q94409621 P2093 "Massimo D’Apuzzo" @default.
- Q94409621 P2093 "Megan Gilchrist" @default.
- Q94409621 P2093 "Michael Barish" @default.
- Q94409621 P2093 "Phil Potter" @default.
- Q94409621 P2093 "Revathiswari Tirughana" @default.
- Q94409621 P2093 "Rex Moats" @default.
- Q94409621 P2093 "Soraya Aramburo" @default.
- Q94409621 P2093 "Suzette Blanchard" @default.
- Q94409621 P2093 "Timothy Synold" @default.
- Q94409621 P304 "vi232-vi233" @default.
- Q94409621 P31 Q13442814 @default.
- Q94409621 P356 "10.1093/NEUONC/NOX168.947" @default.
- Q94409621 P433 "Suppl 6" @default.
- Q94409621 P478 "19" @default.
- Q94409621 P50 Q90051514 @default.
- Q94409621 P577 "2017-11-06T00:00:00Z" @default.
- Q94409621 P921 Q2944097 @default.
- Q94409621 P921 Q5452194 @default.
- Q94409621 P932 "5693135" @default.